removing scenes showing suicide, or addressed by including suicide hotline numbers in each episode. These strategies could be retrofitted to the released episodes, included in the planned second season, or applied to other programs. Moreover, programs might undergo testing to evaluate any effect on public health outcomes before release to minimize societal harms.
Association of Frequency of Lipid Testing With Changes in Lipid-Lowering Therapy
Statins are among the most commonly prescribed medications in the United States and are effective for prevention of cardiovascular events.
1 Recent lipid management guidelines no longer recommend treating to a target low-density lipoprotein (LDL) level and instead favor a risk-assessment approach. 2 Though there is insufficient data to show that monitoring lipids leads to meaningful improvements in clinical outcomes or adherence to pharmacologic treatment, 3 US guidelines recommend lipid monitoring every 3 to 12 months, whereas European guidelines advise annual lipid monitoring among patients receiving therapy. 2, 4, 5 This study aimed to understand clinician rationale for ordering monitoring lipid panels among patients on statin therapy and to determine how often treatment changes occur as a result of testing.
Methods | The study protocol was approved by the Colorado Multiple institutional review board, and informed consent waiver was granted because all data were collected as part of usual patient care. We identified 4945 patients aged 40 to 79 years at the University of Colorado Hospital, who had been seen by a primary care physician in the past 12 months and had been recieving statin therapy for longer than 3 years. We reviewed all medical records between November 1, 2012, and November 1, 2015, from a random sample of 210 of these patients. Clinician rationale for ordering lipid testing and changes to lipid lowering therapy in the following 12 months were assessed. Table 2 and were uncommon irrespective of lipid-lowering indication.
Discussion | Our data indicate that most monitoring lipid tests result in no change in lipid-lowering therapy. The high frequency of testing may reflect adherence to current guidelines, practice habits stemming from the historic treat-totarget approach, patient expectations, and a perception that lipid testing may allow for monitoring adherence to therapy.
We suspect that the rarity of treatment changes was owing to the dearth of data supporting LDL or triglyceride targets, as well as guidelines that now advocate a riskstratification approach though still recommend routine lipid monitoring.
2,4-6 Because the key clinical decision has shifted from treatment to an LDL goal to mitigating cardiovascular risk, the utility of lipid monitoring may be diminished. An important strength of our study is the rigorous review of patient medical charts, which permitted insights into clinician rationale for ordering monitoring lipid panels in patients already recieving treatment. Study limitations include its single center design and data collection was limited to the data available via medical chart review. In addition, our sample had a high proportion of patients recieving statins for primary prevention, and may not be applicable to populations with higher rates of known atherosclerotic cardiovascular disease or use of nonstatin medications, such as PCSK9 inhibitors.
Our study raises the question of the utility of routine lipid monitoring. The appropriate frequency of lipid testing is uncertain. As attention to value-based care increases nationally, this may be a target for cost savings and warrants further study. Karen Stenehjem, MD Dawn Herren, MD Gerald Pulver, PhD Brandon Combs, MD 
Association of Insurance Gains and Losses With Access to Prescription Drugs
Prescription drugs can effectively treat many diseases, improving quality of life, life expectancy, and population health. However, prescription drug spending has been rising rapidly in the United States 1 resulting in concerns about affordability and patient access. Health insurance is strongly associated with prescription drug access in cross-sectional studies, 2,3 but estimates may partly reflect differences between individuals with and without insurance, rather than effects of insurance coverage. To address this limitation, we used longitudinal data from the nationally representative Medical Expenditure Panel Survey (MEPS) to assess the effects of insurance gains and losses on prescription drug access.
Methods | Using longitudinal MEPS data spanning from 2008 to 2014, we categorized adults aged 18 to 64 years by insurance coverage during 2-year panels: (1) continuously insured (n = 38 231); (2) insured year 1 and lost coverage for at least 6 months in year 2 (n = 1320); (3) continuously uninsured (n = 13 516); and (4) uninsured year 1 and gained coverage for at least 6 months in year 2 (n = 1619). Unmet need for prescription drugs was measured in year 1 and year 2 based on responses to questions about delays or inability to obtain needed prescription drugs. We compared unmet need in years 1 and 2 across the 4 insurance categories and controlled for patient characteristics associated with insurance coverage and medical need (ie, age, sex, race and ethnicity, and time-varying measures of self-reported health, number of chronic conditions, and income as a percentage of federal poverty line) with a multivariable linear probability model using STATA statistical software (version 14, STATA corp). The study was covered under an institutional review board agreement designed for the Medical Expenditure Panel Survey with regard to approval and patient written informed consent.
Results | Among individuals with continuous coverage, the percent with unmet need for prescription drugs was low in years 1 and 2 (3.2% and 3.3%, respectively). In contrast, among individuals who had coverage in year 1 but lost it in year 2, the percent with unmet need more than doubled, from 3.1% to 6.6% (difference, 3.5%; 95% CI, 1.3 to 6.1; P < .05). Adjusted estimates were similar ( Figure 1 ) and increases in unmet need for those losing insurance were significantly greater than for the continuously insured. Among individuals continuously uninsured, unmet need was similar in year 1 and year 2 (6.2% and 5.5%, respectively). However, initially uninsured individuals who gained coverage in year 2 had a 3.4 percentage point decline in unmet need (8.8% to 5.4%; 95% CI, −5.9 to −1.3; P < .05). Adjusted estimates were similar ( Figure 2 ) and declines in unmet need for those gaining insurance were significantly greater than for the continuously uninsured. Findings were robust in sensitivity analyses of duration of insurance loss or gain and all combinations of time-varying self-reported health and individual chronic conditions. Discussion | Our findings that unmet need for prescription drugs declined among initially uninsured adults who gained coverage and doubled among initially insured adults who Estimates from multivariable linear probability model controlling for the effects of age, sex, and race/ethnicity in year 1 and time-varying measures of household income as a percentage of the federal poverty line, self-reported health, and number chronic conditions (coronary heart disease, angina, myocardial infarction, other heart disease, stroke, emphysema, high cholesterol, diabetes, arthritis, and asthma). Decrease in unmet need for those gaining health insurance in Year 2 was significantly greater than for the continuously uninsured. Estimates from multivariable linear probability model controlling for the effects of age, sex, and race/ethnicity in year 1 and time-varying measures of household income as a percentage of the federal poverty line, self-reported health, and number of chronic conditions (coronary heart disease, angina, myocardial infarction, other heart disease, stroke, emphysema, high cholesterol, diabetes, arthritis, and asthma). Increase in unmet need for those losing health insurance in Year 2 was significantly greater than for the continuously insured.
